粪便丙酮酸激酶-M2（肿瘤M2-PK）检测：一种用于结直肠癌的新筛查概念。
Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
作者信息
Ewald Nils, Schaller Markus, Bayer Martin, Akinci Ahmet, Bretzel Reinhard G, Kloer Hans-Ulrich, Hardt Philip D
机构信息
Third Medical Department, University Hospital Giessen and Marburg, Giessen Site, Germany.
出版信息
Anticancer Res. 2007 Jul-Aug;27(4A):1949-52.
BACKGROUND
Colorectal cancer (CRC) is a disease with major impact on public health and public health costs. Colonoscopy is purportedly the best screening tool for CRC. However, the acceptance by the general population is very poor. Therefore evaluation of additional screening tools is of great interest.
PATIENTS AND METHODS
The use of M2-PK measurement in the feces has been reported in 6 studies to date. The data of these studies were analysed and critically reviewed. Additionally, 1,906 persons undergoing routine health care check-up provided stool samples for M2-PK measurement.
RESULTS
The overall sensitivity of M2-PK is 77.9% for CRC. Specificity ranges from 74.3 to 83.3%. Of the 1,906 screened persons, 90.4% had results within the normal range, while 9.6% had elevated results.
CONCLUSION
Measurement of tumor M2-PK in feces seems to be the most promising tool for CRC screening at the present time. In combination with colonoscopy, this test should hence be recommended for CRC screening programs.
背景
结直肠癌（CRC）是一种对公众健康和公共卫生成本有重大影响的疾病。结肠镜检查据称是结直肠癌最佳的筛查工具。然而，普通人群对其接受度非常低。因此，对其他筛查工具的评估具有重要意义。
患者与方法
迄今为止，已有6项研究报道了粪便中M2-PK检测的应用。对这些研究的数据进行了分析和严格审查。此外，1906名接受常规健康检查的人员提供了粪便样本用于M2-PK检测。
结果
M2-PK对结直肠癌的总体敏感性为77.9%。特异性范围为74.3%至83.3%。在1906名接受筛查的人员中，90.4%的检测结果在正常范围内，而9.6%的结果升高。
结论
粪便中肿瘤M2-PK检测目前似乎是结直肠癌筛查最具前景的工具。因此，结合结肠镜检查，该检测应推荐用于结直肠癌筛查项目。
Zotero 插件